GEMPHARMATECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.47 CNY | -4.30% |
|
-6.10% | -48.04% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 9,860 | 8,262 | 4,293 | - | - |
| Enterprise Value (EV) 1 | 9,860 | 8,262 | 4,293 | 4,293 | 4,293 |
| P/E ratio | 57.3 x | 51.7 x | 20.9 x | 16.6 x | 14 x |
| Yield | - | 0.79% | 0.33% | 0.48% | 0.62% |
| Capitalization / Revenue | 19.1 x | 13.3 x | 5.55 x | 4.41 x | 3.82 x |
| EV / Revenue | 19.1 x | 13.3 x | 5.55 x | 4.41 x | 3.82 x |
| EV / EBITDA | 45 x | 37.9 x | 15 x | 12.3 x | 10.5 x |
| EV / FCF | - | - | 71.5 x | 76.7 x | 30.9 x |
| FCF Yield | - | - | 1.4% | 1.3% | 3.24% |
| Price to Book | 4.99 x | 3.89 x | 1.87 x | 1.7 x | 1.54 x |
| Nbr of stocks (in thousands) | 410,000 | 410,000 | 410,000 | - | - |
| Reference price 2 | 24.05 | 20.15 | 10.47 | 10.47 | 10.47 |
| Announcement Date | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | 516.5 | 622.2 | 772.8 | 972.9 | 1,125 |
| EBITDA 1 | 219.2 | 218.2 | 286.3 | 347.7 | 408.5 |
| EBIT 1 | 174 | 160.9 | 217.1 | 277 | 327.8 |
| Operating Margin | 33.68% | 25.86% | 28.09% | 28.47% | 29.13% |
| Earnings before Tax (EBT) 1 | 173.7 | 161.3 | 216.2 | 276.3 | 326.5 |
| Net income 1 | 164.6 | 159 | 205 | 257.3 | 308.6 |
| Net margin | 31.87% | 25.55% | 26.53% | 26.45% | 27.43% |
| EPS 2 | 0.4200 | 0.3900 | 0.5000 | 0.6300 | 0.7500 |
| Free Cash Flow 1 | - | - | 60 | 56 | 139 |
| FCF margin | - | - | 7.76% | 5.76% | 12.35% |
| FCF Conversion (EBITDA) | - | - | 20.95% | 16.1% | 34.03% |
| FCF Conversion (Net income) | - | - | 29.27% | 21.76% | 45.04% |
| Dividend per Share 2 | - | 0.1600 | 0.0350 | 0.0500 | 0.0650 |
| Announcement Date | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2024 Q1 |
|---|---|
| Net sales 1 | 157.1 |
| EBITDA | - |
| EBIT | - |
| Operating Margin | - |
| Earnings before Tax (EBT) | - |
| Net income 1 | 29.48 |
| Net margin | 18.77% |
| EPS | - |
| Dividend per Share | - |
| Announcement Date | 4/27/24 |
1CNY in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | - | 60 | 56 | 139 |
| ROE (net income / shareholders' equity) | 10.6% | 7.76% | 8.95% | 10.2% | 11% |
| ROA (Net income/ Total Assets) | 7.31% | 6.56% | 7.5% | 8.43% | 8.9% |
| Assets 1 | 2,254 | 2,422 | 2,733 | 3,052 | 3,467 |
| Book Value Per Share 2 | 4.820 | 5.180 | 5.600 | 6.160 | 6.790 |
| Cash Flow per Share 2 | 0.2600 | 0.2800 | 0.5800 | 0.7400 | 0.9000 |
| Capex 1 | 190 | 206 | 181 | 162 | 156 |
| Capex / Sales | 36.82% | 33.08% | 23.48% | 16.67% | 13.84% |
| Announcement Date | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.47
CNY
Average target price
18.71
CNY
Spread / Average Target
+78.70%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -48.04% | 591M | |
| +21.85% | 46.44B | |
| +37.63% | 39.1B | |
| -8.05% | 38.76B | |
| +29.04% | 31.24B | |
| -13.75% | 25.8B | |
| +10.65% | 25.9B | |
| +38.43% | 13.12B | |
| -6.92% | 11.32B | |
| -12.29% | 10.68B |
- Stock Market
- Equities
- 688046 Stock
- Financials GemPharmatech Co., Ltd.
